AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2207301 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic ibuprofen 400 mg
Number of subjects: 4
Study 2207301 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic ibuprofen 800 mg
Number of subjects: 4
Study 2207301 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic ibuprofen 1200 mg
Number of subjects: 4
Study 2207301 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic ibuprofen (all doses)
Number of subjects: 4
Study 6161895 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 13
Study 6161895 — intervention group
Group type: COMPARATOR
Intervention: Saralasin
Number of subjects: 13
Study 6161895 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril in normal subjects
Number of subjects: 13
Study 6161895 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril in patients with essential hypertension
Number of subjects: 13
Study 6161895 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril in patients with renovascular hypertension (RVH)
Number of subjects: 13
Study 6161895 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin in patients with RVH
Number of subjects: 13
Study 6161895 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin in patients with essential hypertension
Number of subjects: 13
Study 31044719 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus fluoropyrimidine and cisplatin
Number of subjects: 0
Study 26945195 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine consultation
Number of subjects: 30
Study 26945195 — intervention group
Group type: COMPARATOR
Intervention: Telephone consultation (control)
Number of subjects: 30
Study 26448791 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced CDSS with autism module
Number of subjects: 126
Study 26448791 — intervention group
Group type: COMPARATOR
Intervention: Control clinics (no enhanced CDSS module)
Number of subjects: 126
Study 24176438 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-Eluting Endeavor Sprint stent (E-ZES)
Number of subjects: 1600
Study 24176438 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 1600
Study 21128873 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT
Number of subjects: 130
Study 21128873 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 130
Study 21128873 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CBT and Sertraline
Number of subjects: 130
Study 21128873 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy
Number of subjects: 130
Study 19417610 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 54
Study 19417610 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 54
Study 17911873 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided dosing within a computerized provider order entry (CPOE) system
Number of subjects: 2981
Study 17911873 — intervention group
Group type: COMPARATOR
Intervention: Control group (no guided dosing)
Number of subjects: 2981
Study 17911873 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided dosing within a CPOE system
Number of subjects: 2981
Study 15329426 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant surfactant protein C-based surfactant (up to four intratracheal doses within 24 hours)
Number of subjects: 448
Study 15329426 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus recombinant surfactant protein C-based surfactant
Number of subjects: 448
Study 15329426 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 448
Study 11583188 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted intra-operative radiotherapy (Targit), delivered doses of 5-20 Gy over about 22 min
Number of subjects: 25
Study 11583188 — intervention group
Group type: COMPARATOR
Intervention: Conventional six-week course of radiotherapy
Number of subjects: 25
Study 9820298 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated dosing (n=137)
Number of subjects: 285
Study 9820298 — intervention group
Group type: COMPARATOR
Intervention: Traditional dosing (n=148)
Number of subjects: 285
Study 9820298 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated dosing (stabilisation patients)
Number of subjects: 285
Study 9820298 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated dosing (stable patients)
Number of subjects: 285
Study 8548110 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0
Study 8548110 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0
Study 8548110 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (low doses)
Number of subjects: 0
Study 2611359 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of cyclosporine
Number of subjects: 8
Study 2611359 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of cyclosporine
Number of subjects: 8
Study 319730 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% DMSO
Number of subjects: 0
Study 319730 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1%
Number of subjects: 0
Study 319730 — intervention group
Group type: COMPARATOR
Intervention: 90% DMSO
Number of subjects: 0
Study 319730 — intervention group
Group type: COMPARATOR
Intervention: 100% DMSO
Number of subjects: 0
Study 319730 — intervention group
Group type: COMPARATOR
Intervention: 50% to 70% DMSO
Number of subjects: 0
Study 29380956 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 38
Study 29380956 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol blend (PPB)
Number of subjects: 38
Study 29380956 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspase 8
Number of subjects: 38
Study 29380956 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspase 3 and Caspase 9
Number of subjects: 38
Study 26383586 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-augmented verbal feedback
Number of subjects: 0
Study 26383586 — intervention group
Group type: COMPARATOR
Intervention: Verbal only feedback
Number of subjects: 0
Study 25421363 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue self-management (FSM) intervention, which included two sessions of a nurse-delivered protocol and a self-help book.
Number of subjects: 73
Study 25421363 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue self-management (FSM) intervention
Number of subjects: 73
Study 25421363 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 73
Study 23292674 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiomesh in IHR
Number of subjects: 100
Study 23292674 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiomesh in VHR
Number of subjects: 100
Study 20813346 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin ophthalmic solution 1%
Number of subjects: 0
Study 20813346 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin ophthalmic solution 0.5%
Number of subjects: 0
Study 18802150 — intervention group
Group type: COMPARATOR
Intervention: VACA (vincristine, dactinomycin, cyclophosphamide, doxorubicin)
Number of subjects: 647
Study 18802150 — intervention group
Group type: COMPARATOR
Intervention: EVAIA (vincristine, dactinomycin, ifosfamide, doxorubicin, etoposide)
Number of subjects: 647
Study 15652870 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsolateral region in boys with autism
Number of subjects: 0
Study 15652870 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (normal boys)
Number of subjects: 0
Study 15652870 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsolateral and medial frontal regions in boys with autism aged 2 to 5 years
Number of subjects: 0
Study 15652870 — intervention group
Group type: EXPERIMENTAL
Intervention: Precentral gyrus and orbital cortex in boys with autism
Number of subjects: 0
Study 12847482 — intervention group
Group type: EXPERIMENTAL
Intervention: FP 400 microg twice a day plus SALM 50 microg twice a day (FP 400 + SALM)
Number of subjects: 56
Study 12847482 — intervention group
Group type: COMPARATOR
Intervention: FP 200 microg twice a day (FP400)
Number of subjects: 56
Study 12847482 — intervention group
Group type: COMPARATOR
Intervention: FP 1000 microg twice a day (FP1000)
Number of subjects: 56
Study 10502079 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 min of cycle ergometer exercise at 90% VO2(max) (AO)
Number of subjects: 8
Study 10502079 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard circuit-training routine (CT)
Number of subjects: 8
Study 10502079 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 h cycle ergometer exercise at 60% VO2(max) (Long)
Number of subjects: 8
Study 10502079 — intervention group
Group type: COMPARATOR
Intervention: Seated for 5 h (Control)
Number of subjects: 8
Study 8759045 — intervention group
Group type: EXPERIMENTAL
Intervention: Freedom to volunteer or withhold information
Number of subjects: 0
Study 8759045 — intervention group
Group type: EXPERIMENTAL
Intervention: Accuracy incentive
Number of subjects: 0
Study 8759045 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring effectiveness
Number of subjects: 0
Study 1714709 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (enoxaparin) 40.6 mg subcutaneously once daily
Number of subjects: 246
Study 1714709 — intervention group
Group type: COMPARATOR
Intervention: Dextran 70 (standard regimen)
Number of subjects: 246
Study 1714709 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (enoxaparin)
Number of subjects: 246
Study 7082534 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg sublingual buprenorphine
Number of subjects: 15
Study 7082534 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg sublingual buprenorphine
Number of subjects: 15
Study 7082534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6489425 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 62.5 micrograms/kg i.v.
Number of subjects: 26
Study 6489425 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 7.5 micrograms/kg i.v.
Number of subjects: 26
Study 30806807 — intervention group
Group type: EXPERIMENTAL
Intervention: Local application of MMR vaccine after surgery
Number of subjects: 31
Study 30806807 — intervention group
Group type: COMPARATOR
Intervention: Surgical excision alone (Control)
Number of subjects: 31
Study 30371183 — intervention group
Group type: EXPERIMENTAL
Intervention: HAS-BLED score
Number of subjects: 3550
Study 30371183 — intervention group
Group type: COMPARATOR
Intervention: GARFIELD-AF score
Number of subjects: 3550
Study 26501882 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus-modified criteria (CM-2012)
Number of subjects: 100
Study 26501882 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified tissue orientation protocol
Number of subjects: 100
Study 26501882 — intervention group
Group type: COMPARATOR
Intervention: Conventional tissue-handling protocol (CP)
Number of subjects: 100
Study 24630163 — intervention group
Group type: EXPERIMENTAL
Intervention: Whiplash patients
Number of subjects: 60
Study 24630163 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 60
Study 22923328 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinkable solution of 70 mg/100 mL alendronate
Number of subjects: 128
Study 22923328 — intervention group
Group type: COMPARATOR
Intervention: Tablets of alendronate
Number of subjects: 128
Study 20599461 — intervention group
Group type: EXPERIMENTAL
Intervention: Medications for bipolar disorder
Number of subjects: 152
Study 17662438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral mydriatics (150 muL of phenylephrine 1.5% and lidocaine 1%)
Number of subjects: 22
Study 17662438 — intervention group
Group type: COMPARATOR
Intervention: Conventional topical mydriatics and intracameral lidocaine
Number of subjects: 22
Study 17662438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral mydriatics
Number of subjects: 22
Study 17662438 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal edema
Number of subjects: 22
Study 16238797 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled steroids during allergen exposure
Number of subjects: 0
Study 16238797 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment during allergen exposure
Number of subjects: 0
Study 16238797 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled steroids
Number of subjects: 0
Study 16238797 — intervention group
Group type: COMPARATOR
Intervention: Low-dose allergen exposure
Number of subjects: 0
Study 12915593 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP plus G‐CSF
Number of subjects: 389
Study 12915593 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 389
Study 10202647 — intervention group
Group type: EXPERIMENTAL
Intervention: PE + CBT
Number of subjects: 56
Study 10202647 — intervention group
Group type: COMPARATOR
Intervention: PE-alone
Number of subjects: 56
Study 8727431 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume (VT) increased to 12-14 ml/kg for 30 min
Number of subjects: 15
Study 8727431 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume (VT) decreased to 6-8 ml/kg for 30 min
Number of subjects: 15
Study 8727431 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume (VT) increased to 12-14 ml/kg
Number of subjects: 15
Study 8727431 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume (VT) decreased to 6-8 ml/kg
Number of subjects: 15
Study 8727431 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PaCO2 levels
Number of subjects: 15
Study 1985823 — intervention group
Group type: EXPERIMENTAL
Intervention: Progabide (PGB)
Number of subjects: 59
Study 1985823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 6339999 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium canrenoate (200 mg/day for 21 days)
Number of subjects: 21
Study 6339999 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone (200 mg/day for 21 days)
Number of subjects: 21
Study 30867041 — intervention group
Group type: EXPERIMENTAL
Intervention: Profender® spot-on (emodepside 2.1% and praziquantel 8.6%) administered on days 0 and 14
Number of subjects: 16
Study 30867041 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 16
Study 30867041 — intervention group
Group type: EXPERIMENTAL
Intervention: Profender® spot-on (emodepside 2.1% and praziquantel 8.6%)
Number of subjects: 16
Study 27498023 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg twice per day (b.i.d.; n = 192)
Number of subjects: 288
Study 27498023 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib 400 mg b.i.d. (n = 96)
Number of subjects: 288
Study 27498023 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib in patients with ECOG PS 0
Number of subjects: 288
Study 27498023 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib in patients with ECOG PS 0
Number of subjects: 288
Study 27498023 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib in patients with ECOG PS 1
Number of subjects: 288
Study 27498023 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib in patients with ECOG PS 1
Number of subjects: 288
Study 25833970 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid emulsion 1 (LE1; acid stable, 0.33 μm)
Number of subjects: 18
Study 25833970 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid emulsion 2 (LE2; acid stable, 52 μm)
Number of subjects: 18
Study 25833970 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid emulsion 3 (LE3; acid unstable, solid fat, 0.32 μm)
Number of subjects: 18
Study 25833970 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid emulsion 4 (LE4; acid unstable, liquid fat, 0.38 μm)
Number of subjects: 18
Study 24938562 — intervention group
Group type: EXPERIMENTAL
Intervention: selumetinib, 75 mg orally twice daily on a continual basis (n=50)
Number of subjects: 120
Study 24938562 — intervention group
Group type: COMPARATOR
Intervention: chemotherapy (temozolomide, 150 mg/m2 orally daily for 5 of every 28 days, or dacarbazine, 1000 mg/m2 intravenously every 21 days) (n=51)
Number of subjects: 120
Study 24938562 — intervention group
Group type: EXPERIMENTAL
Intervention: selumetinib
Number of subjects: 120
Study 24938562 — intervention group
Group type: COMPARATOR
Intervention: chemotherapy
Number of subjects: 120
Study 23136545 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin treatment
Number of subjects: 104
Study 19489810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient room
Number of subjects: 62
Study 19489810 — intervention group
Group type: COMPARATOR
Intervention: Standard room
Number of subjects: 62
Study 18091308 — intervention group
Group type: EXPERIMENTAL
Intervention: Aniseikonia Inspector Version 1
Number of subjects: 27
Study 18091308 — intervention group
Group type: EXPERIMENTAL
Intervention: Aniseikonia Inspector Version 2
Number of subjects: 27
Study 15003736 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Carbohydrate Diet (LCH)
Number of subjects: 34
Study 15003736 — intervention group
Group type: COMPARATOR
Intervention: High Carbohydrate Diet (HCH)
Number of subjects: 34
Study 12170275 — intervention group
Group type: EXPERIMENTAL
Intervention: Education about NRL allergies and introduction of powder-free NRL gloves
Number of subjects: 3000000
Study 12170275 — intervention group
Group type: EXPERIMENTAL
Intervention: Purchase of powder-free NRL examination gloves
Number of subjects: 3000000
Study 12170275 — intervention group
Group type: EXPERIMENTAL
Intervention: Purchase of powder-free NRL sterile gloves
Number of subjects: 3000000
Study 12170275 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention strategies including education and regulations
Number of subjects: 3000000
Study 10483952 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity arterial disease (LEAD) defined as an ankle/arm systolic blood pressure ratio of 0.90 or less.
Number of subjects: 405
Study 10483952 — intervention group
Group type: COMPARATOR
Intervention: No lower extremity arterial disease (non-LEAD)
Number of subjects: 405
Study 10483952 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity arterial disease (LEAD)
Number of subjects: 405
Study 8963892 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline tilt testing for 45 minutes
Number of subjects: 145
Study 8963892 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline infusion
Number of subjects: 145
Study 8963892 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium bolus (10 mg)
Number of subjects: 145
Study 8963892 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent syncope
Number of subjects: 145
Study 8963892 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant structural heart disease (SHD) or sudden diminished consciousness (SDC)
Number of subjects: 145
Study 8963892 — intervention group
Group type: EXPERIMENTAL
Intervention: Age below or above 50 years
Number of subjects: 145
Study 8963892 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of factors (age, SHD, SDC, recurrent syncope)
Number of subjects: 145
Study 8963892 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional yield of isoprenaline
Number of subjects: 145
Study 8963892 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional yield of edrophonium
Number of subjects: 145
Study 8963892 — intervention group
Group type: EXPERIMENTAL
Intervention: Second drug required for positive result
Number of subjects: 145
Study 1875966 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracentesis plus intravenous albumin
Number of subjects: 89
Study 1875966 — intervention group
Group type: COMPARATOR
Intervention: LeVeen peritoneovenous shunt
Number of subjects: 89
Study 6617274 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 20 mg three times daily
Number of subjects: 19
Study 6617274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30068518 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention focused on plant foods, low glycemic load, low in saturated fats and alcohol
Number of subjects: 226
Study 30068518 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA) intervention combining daily moderate intensity activities and one weekly supervised session of more strenuous activity
Number of subjects: 226
Study 30068518 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dietary and physical activity interventions
Number of subjects: 226
Study 30068518 — intervention group
Group type: COMPARATOR
Intervention: General recommendations (control group)
Number of subjects: 226
Study 29575010 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined diabetes peer support and usual care
Number of subjects: 1121
Study 29575010 — intervention group
Group type: EXPERIMENTAL
Intervention: One-to-one diabetes peer support and usual care
Number of subjects: 1121
Study 29575010 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1121
Study 27580228 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Release Program (6 weeks)
Number of subjects: 50
Study 27580228 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control Group
Number of subjects: 50
Study 24488447 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 122
Study 24488447 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 122
Study 23776460 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral STN‐DBS (on-stimulation)
Number of subjects: 13
Study 23776460 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral STN‐DBS (off-stimulation)
Number of subjects: 13
Study 23776460 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 13
Study 20934654 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 347
Study 20934654 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 347
Study 18087207 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic Family Therapy (SFT) associated with routine psychiatric treatment
Number of subjects: 40
Study 18087207 — intervention group
Group type: COMPARATOR
Intervention: Routine psychiatric treatment alone
Number of subjects: 40
Study 15673749 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (M group)
Number of subjects: 187
Study 15673749 — intervention group
Group type: COMPARATOR
Intervention: Quinine plus Sulphalene-Pyrimethamine (QSP group)
Number of subjects: 187